Results 31 to 40 of about 20,787 (190)

Improved Cardiovascular and Cardiometabolic Risk in Patients With Type 1 Diabetes and Autoimmune Polyglandular Syndrome Switched From Glargine to Degludec Due to Hypoglycaemic Variability

Frontiers in Endocrinology, 2018
Background: Cardiovascular disease is a frequent complication of type 1 diabetes (T1D). We evaluated the effectiveness of switching from glargine to degludec in reducing the cardiovascular risk factors, the Framingham risk score (FRS) and visceral ...
Valentina Guarnotta, Giulia Di Bella, Giuseppe Pillitteri, Alessandro Ciresi, Carla Giordano   +4 more
doaj   +1 more source

Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study. [PDF]

PLoS ONE, 2011
BACKGROUND: Preclinical and observational studies raise the concern about the safety of insulin glargine in terms of cancer initiation and promotion.
Chia-Hsuin Chang, Sengwee Toh, Jou-Wei Lin, Shu-Ting Chen, Chuei-Wen Kuo, Lee-Ming Chuang, Mei-Shu Lai   +6 more
doaj   +1 more source

Remission of tuberculosis following control of glycemic excursions in a patient with type 2 diabetes mellitus: A case report

Journal of Diabetology, 2022
Rationale: Tuberculosis (TB) and diabetes mellitus (DM) are converging epidemics, each worsening the morbidity of the other. Chronic hyperglycemia is associated with dysfunctional immunity to Mycobacterium in patients with DM and, therefore, is likely to
Anand Hinduja
doaj   +1 more source

Comparison of Safety and Efficacy of Insulin Glargine and Neutral Protamine Hagedorn Insulin in Older Adults with Type 2 Diabetes Mellitus: Results from a Pooled Analysis [PDF]

, 2012
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90150/1/jgs3773 ...
Blaum, Caroline S., Chang, Annette, Gao, Ling, Halter, Jeffrey B., Lee, Pearl G., Vlajnic, Aleksandra   +5 more
core   +1 more source

Place of insulin therapy in current approaches to the treatment of type 2 diabetes

Медицинский совет, 2016
Type 2 diabetes mellitus (T2DM) is a high risk factor for the development of macrovascular complications. Several large studies have demonstrated the fundamental role of early extensive blood glucose control in the prevention of these complications.
O. Y. Gurova, V. V. Fadeev
doaj   +1 more source

A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials [PDF]

, 2013
Aim: To evaluate health-related quality of life (health utility) scores in patients with diabetes receiving insulin degludec (IDeg) or insulin glargine (IGlar).
Bjorner, JB, Christensen, T, Evans, M, Freemantle, N, Wolden, ML   +4 more
core   +1 more source

Insulin/carbohydrates ratio during the first 6‐month therapy with insulin degludec in a paediatric population with type 1 diabetes previously treated with insulin glargine. An observational longitudinal study

Endocrinology, Diabetes & Metabolism, 2020
Background No data exist about the changes induced by the transition from first‐generation long‐acting insulins to second‐generation long‐acting analogues in the paediatric population.
Stefano Tumini, Olimpia Iacono, Laura Comegna, Elisabetta Fioretti, Paola Guidone, Gabriella Levantini, Daniele Panichi, Milena Catenaro, Ilaria Rossi, Flavia Amaro, Giusi Graziano, Maria Chiara Rossi, Paola Cipriano   +12 more
doaj   +1 more source

Real World Effectiveness of fixed combination of glargine 100 U/ml and lixisenatide therapy in outpatients with Type 2 Diabetes: A Retrospective Cohort Study SOLO

Сахарный диабет, 2022
Background: The effectiveness and safety of a fixed combination of insulin glargine 100 ME/ml and lixisenatide for treatment of patients with type 2 diabetes (T2DM) has been demonstrated in randomized clinical trials, but there are still not enough data ...
M. B. Antsiferov, N. A. Demidov, M. A. Balberova, T. I. Safronova, O. A. Mishra, S. G. Magomedova   +5 more
doaj   +1 more source

Insulin Toujeo® — a Novel Basal Long-Acting Insulin Formulation. Part 2. Clinical Efficacy and Safety

Mìžnarodnij Endokrinologìčnij Žurnal, 2015
This review, consisting of two parts, considers a new formulation of insulin glargine (rDNA origin) in the form of injections 300 U/ml (Gla-300, Toujeo®).
V.V. Poltorak, N.А. Kravchun, M.Yu. Gorshunska   +2 more
doaj   +1 more source

When intensive insulin therapy (MDi) fails in patients with type 2 diabetes: Switching to GLP-1 receptor agonist versus insulin pump [PDF]

, 2016
Treatment with insulin, alone or with oral or injectable hypoglycemic agents, is becoming increasingly common in patients with type 2 diabetes. However, approximately 40% of patients fail to reach their glycemic targets with the initially prescribed ...
Castaneda, Javier, Cohen, Ohad, FILETTI, SEBASTIANO, Glandt, Mariela, MARANGHI, MARIANNA   +4 more
core   +2 more sources